Results 171 to 180 of about 56,774 (264)

Snapshot Look at Castleman Disease

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Castleman disease (CD) is a rare and heterogeneous group of lymphoproliferative disorders characterised by abnormal proliferation of lymphoid tissue. First described in the 1950s, it has since been classified into two major clinical forms: unicentric CD (UCD), involving a single lymph node region and multicentric CD (MCD), which affects ...
Ciprian Jitaru, Natalia Zlampa, Delia Dima, Anca Bojan, Mihnea Zdrenghea, Laura Urian, David Kegyes, Anamaria Bancos, Maria Santa, Andrei Ivancuta, Bobe Petrushev, Madalina Nistor, Bogdan Tigu, Catalin Constantinescu, Bogdan Fetica, Maria Puiu, Mihai‐Stefan Muresan, Ciprian Tomuleasa   +17 more
wiley   +1 more source

Clinical Experience With Biologic Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis: A Case Report and Review of Literature. [PDF]

Clin Case Rep
Nazneen PS, Dorji T, Yangzom S, Natarajan RV.   +3 more
europepmc   +1 more source

A Comparative Study of Polysomnography‐Derived Sleep Disturbance in People Living With Multiple Sclerosis Compared to Matched Controls From the General Population

Journal of Sleep Research, Volume 35, Issue 1, February 2026.
ABSTRACT Sleep structure and sleep disorders were compared between people with multiple sclerosis (MS; n = 39) and age, sex, and BMI‐matched members of the general population (n = 39) using overnight polysomnography (PSG). Compared to population controls, people with MS had a higher prevalence of periodic limb movement disorder (PLMD; 59% vs.
Amy C. Reynolds, Emma Thomas, Yohannes Adama Melaku, Hanna A. Hensen, Arun V. Krishnan, Simon C. Gandevia, Stephen R. Lord, Peter R. Eastwood, Danny J. Eckert   +8 more
wiley   +1 more source

Adalimumab-Associated Transverse Myelitis Revealing Relapsing-Remitting Multiple Sclerosis in a Patient With Crohn's Disease: A Case Report. [PDF]

Cureus
Gawargeous SS, Elsahy T.
europepmc   +1 more source

Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study. [PDF]

Patient Prefer Adherence
Almroth A, Söderbärg K, Sjöblom I.
europepmc   +1 more source

Alterations of fecal short-chain fatty acids solely in the course of multiple sclerosis: rethinking the gut-brain axis in the early stages of MS. [PDF]

Ther Adv Neurol Disord
Stögbauer J, Kämpfer N, Becker-Dorison A, Schwiertz A, Groppa S, Unger MM, Fousse M.   +6 more
europepmc   +1 more source

The Association Between the Occurrence of Sensory Integration Disorders, Depression, and Chronic Fatigue in Patients with Relapsing-Remitting Multiple Sclerosis. [PDF]

J Clin Med
Machowska-Sempruch K, Masztalewicz M, Meller A, Nowacki P, Pawlukowska W.   +4 more
europepmc   +1 more source

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks [PDF]

, 2018
Dong, Qunming, Hendin, Barry, Huang, Deren, Jhaveri, Mehul, Jones, Daniel L, Livingston, Terrie, Naismith, Robert T, Watson, Crystal, Wray, Sibyl E   +8 more
core   +1 more source

Enterovirus Encephalitis in People With Multiple Sclerosis on Ocrelizumab: Insights From a Multicenter Case Series. [PDF]

Neurol Neuroimmunol Neuroinflamm
Banks SA, Poliakov I, Flanagan EP, Toledano M, Nathoo N.   +4 more
europepmc   +1 more source

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis. [PDF]

Cureus
Chitturi SV, Amith Priyansu J, Sadhu A, Ramisetty H, Pallapothu MR, Kogantii D.   +5 more
europepmc   +1 more source